Real-world evidence and patient preference for subcutaneous versus intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis - initial results from the observational SISTER study.

Ralf GoldStephan SchmidtFlorian DeisenhammerJeremias MotteNils RichterKirsi TaipaleHans Christian SalmenChristian BohlandKsenija Schirduan

Published in: Therapeutic advances in neurological disorders (2024)

This observational (non-interventional) study was registered in the local German PEI register for non-interventional studies (NIS-No. 611) and in the international CTgov register (NCT05304520).

Keyphrases

multiple sclerosis
cross sectional
high dose
low dose
systemic lupus erythematosus
rheumatoid arthritis
disease activity
replacement therapy